BASKING RIDGE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS)
(“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting
autoimmune and select cardiology indications, announces results for the three and nine months ended September 30, 2017.
Highlights of the 2017 third quarter and recent weeks include:
- Enrolled the 70th subject in The Sanford Project: T-Rex Study (the “T-Rex Study”), a prospective, randomized,
placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for
recent-onset type 1 diabetes (“T1D”), which triggered a $2.4 million milestone payment and the delivery of 508,475 shares of
Caladrius common stock as per the terms of the September 2016 private placements;
- Reached 50% of subjects, or 56 patients, treated in the T-Rex Study, which establishes a timeframe for a prescribed interim
analysis when the first 56 patients reach their 6-month follow-up visit; and
- Awarded approximately $2 million as a Small Business Innovative Research (“SBIR”) grant from the National Heart, Lung and
Blood Institute of the National Institutes of Health (“NIH”) to support a Phase 2 clinical study with CLBS14 in patients with
coronary microvascular dysfunction (“CMD”).
Management Commentary
“Throughout the third quarter and following the sale of our contract manufacturing business to Hitachi Chemical, we made
significant progress advancing Caladrius as a purely development-focused biopharmaceutical company and achieved key milestones in a
number of our clinical development programs,” stated David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius.
“Our lead program, the T-Rex study, remains on track to complete enrollment by the end of this year. Additionally, we expect
to have the results of a planned pre-specified interim analysis of the data from the six-month follow-up of the first 56 patients
around the end of the first quarter of 2018.”
“Furthermore, we continue to execute according to our strategy to advance our pipeline programs with collaborative support, such
as grants, partnerships or licensing. During the third quarter 2017, we were pleased to receive an NIH grant to help fund our
Phase 2 study of CLBS14 in CMD. We also continue to receive funding from the California Institute for Regenerative Medicine
(“CIRM”) grant in support of the T-Rex study,” Dr. Mazzo continued. “The successful sale of our PCT manufacturing subsidiary
earlier this year has resulted in Caladrius being well-funded and focused on advancing our clinical development programs, while
also allowing us to opportunistically explore compelling therapeutic prospects through a comprehensive, disciplined and data-driven
process. We look forward to achieving a number of value-creating milestones during the remainder of the year and into 2018.”
Third Quarter Financial Highlights
Note: Effective with the sale of PCT to Hitachi in the second quarter of 2017, all PCT-related activities and gain on sale
results will be reported as discontinued operations. All remaining operations will be reported as continuing
operations. In addition, all prior year comparative financial results will restate PCT operations as discontinued
operations.
Research and development (R&D) expenses for the third quarter of 2017 of $3.2 million increased 8% compared with $3.0
million in the third quarter of 2016, as the Company focuses its R&D efforts on the ongoing Phase 2 T-Rex Study and
preparations for other pipeline programs. Caladrius’ clinical development programs are supported, in part, by grants and
collaborations.
General and administrative (G&A) expenses for the third quarter of 2017 remained flat at $2.9 million, compared with $2.8
million in the third quarter of 2016.
The net loss from continuing operations for the third quarter of 2017 was $3.5 million, compared with the net loss from
continuing operations of $6.1 million for the comparable 2016 period. The continuing operations net loss includes a tax
benefit of $2.4 million, which partially offsets the tax expense reported in discontinued operations.
Loss from discontinued operations during the third quarter of 2016 was $1.2 million. Discontinued operations relate to our
sale of PCT to Hitachi in the second quarter of 2017.
Net loss per share from continuing operations attributable to Caladrius common stockholders for the third quarter of 2017 was
$0.38 per share compared to net loss per share of $0.95 for the same period in 2016.
Nine-Month Financial Highlights
R&D expenses for the first nine months of 2017 decreased 17% to $11.2 million compared with $13.5 million for the same
period in 2016. G&A expenses were $9.1 million for the first nine months of 2017 compared with $10.5 million for first
nine months of 2016. The first nine months of 2017 included $1.7 million of equity compensation expense. This unusually high
expense was due to the acceleration of employee equity stock and option award vesting triggered by the sale of the Company’s PCT
subsidiary to Hitachi.
The net loss from continuing operations for the nine months ended September 30, 2017 was $12.2 million, compared with the net
loss from continuing operations of $25.6 million for the same period of 2016. The continuing operations net loss includes a
tax benefit of $8.3 million, which partially offsets the tax expense reported in discontinued operations.
Income from discontinued operations during the first nine months of 2017 was $37.3 million, which includes a $40.2 million gain
on the sale of PCT (net of $11.6 million taxes), compared with a loss from discontinued operations of $1.6 million in the same
period in 2016.
Net loss per share from continuing operations attributable to Caladrius common stockholders for the nine months ended September
30, 2017 was $1.37 per share compared to net loss per share of $4.23 for the same period in 2016.
Balance Sheet Highlights
As of September 30, 2017, Caladrius had cash, cash equivalents and marketable securities of $59.4 million compared with $7.1
million as of December 31, 2016. During the third quarter of 2017, the Company received an additional $4.4 million as a final net
cash settlement of the PCT transaction, bringing the total received to $79.4 million. Also during the third quarter of 2017, upon
the enrollment of the 70th patient in the T-Rex study, the Company received $2.4 million and delivered 508,475 shares of
Caladrius common stock as per the terms of the September 2016 private placements.
Based on existing programs and projections, the Company expects to have more than $50 million in cash and marketable securities
at year-end 2017. Caladrius also expects less than $5 million of CLBS03 external spending obligations after 2017 to reach the
completion of the T-Rex study, excluding any further CIRM funding. The Company is confident its cash balances and additional grant
funding, along with continued disciplined expense management, will allow it to fund its current business plan beyond 2018.
Conference Call
Caladrius’ management will host a conference call for the investment community beginning today at 4:30 p.m. Eastern Time to
review financial results, provide a Company update and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 877-562-4460 (U.S.) or 513-438-4106
(international) and providing conference ID 6198497. The call will also be broadcast live on the Company’s website at www.caladrius.com/events.
The webcast will be archived on the Company’s website for 90 days.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting
autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo
expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2
trial. CLBS14, CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius’ proprietary
and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and
regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration
for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia is about
to initiate in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based
on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine
regulations. For more information about Caladrius please visit www.caladrius.com.
Safe Harbor for Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March 17, 2017, and in the Company’s other periodic filings with the
SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and
market acceptance, which are outside of its control. You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date of this Press Release. Caladrius does not intend, and disclaims any obligation, to update or revise
any forward-looking information contained in this Press Release or with respect to the matters described herein.
Contacts:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com
LHA Investor Relations
Anne Marie Fields
Senior Vice President
Phone: 212-838-3777
Email: afields@lhai.com
Media:
Caladrius Biosciences, Inc.
Terrance Beckett
Communications and Marketing
Phone: 646-434-2681
Email: tbeckett@caladrius.com
-Tables to Follow-
| |
| Caladrius Biosciences, Inc. |
| Selected Financial Data
(unaudited) |
| (in thousands, except
per share data) |
| |
Three Months Ended
Sept 30, |
|
Nine Months Ended Sept 30, |
| (in thousands, except per share data) |
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
| Statement of Operations Data: |
|
|
|
|
|
|
|
| Research and development |
|
3,187 |
|
|
|
2,959 |
|
|
|
11,191 |
|
|
|
13,496 |
|
| General and administrative |
|
2,943 |
|
|
|
2,769 |
|
|
|
9,082 |
|
|
|
10,514 |
|
| Total operating expenses |
|
6,130 |
|
|
|
5,728 |
|
|
|
20,273 |
|
|
|
24,010 |
|
| Operating loss |
|
(6,130 |
) |
|
|
(5,728 |
) |
|
|
(20,273 |
) |
|
|
(24,010 |
) |
| Other income (expense), net |
|
177 |
|
|
|
5 |
|
|
|
137 |
|
|
|
20 |
|
| Interest expense |
|
(9 |
) |
|
|
(368 |
) |
|
|
(372 |
) |
|
|
(1,601 |
) |
| Loss before income taxes and noncontrolling
interests |
|
(5,962 |
) |
|
|
(6,091 |
) |
|
|
(20,508 |
) |
|
|
(25,591 |
) |
| Benefit from income taxes |
|
(2,414 |
) |
|
|
- |
|
|
|
(8,301 |
) |
|
|
- |
|
| Net loss from continuing
operations |
|
(3,548 |
) |
|
|
(6,091 |
) |
|
|
(12,206 |
) |
|
|
(25,591 |
) |
| Discontinued operations |
|
- |
|
|
|
(1,197 |
) |
|
|
37,330 |
|
|
|
(1,629 |
) |
| Net income (loss) |
|
(3,548 |
) |
|
|
(7,288 |
) |
|
|
25,124 |
|
|
|
(27,220 |
) |
Less - net loss from continuing operations attributable
to noncontrolling
interests |
|
(119 |
) |
|
|
(59 |
) |
|
|
(150 |
) |
|
|
(187 |
) |
Less - net income (loss) from discontinued operations
attributable to
noncontrolling interests |
|
- |
|
|
|
(346 |
) |
|
|
(568 |
) |
|
|
(335 |
) |
Net income (loss) attributable to Caladrius
Biosciences, Inc. common
stockholders |
$ |
(3,429 |
) |
|
$ |
(6,883 |
) |
|
$ |
25,842 |
|
|
$ |
(26,698 |
) |
| |
|
|
|
|
|
|
|
Basic and diluted loss per share attributable
to Caladrius
Biosciences, Inc. common stockholders |
|
|
|
|
|
|
|
| Continuing operations |
$ |
(0.38 |
) |
|
$ |
(0.95 |
) |
|
$ |
(1.37 |
) |
|
$ |
(4.23 |
) |
| Discontinued operations |
$ |
- |
|
|
$ |
(0.13 |
) |
|
$ |
4.30 |
|
|
$ |
(0.22 |
) |
| Caladrius Biosciences, Inc. common
shareholders |
|
(0.38 |
) |
|
|
(1.09 |
) |
|
|
2.94 |
|
|
|
(4.45 |
) |
| Weighted average common
shares outstanding |
|
9,094 |
|
|
|
6,323 |
|
|
|
8,804 |
|
|
|
6,002 |
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
September 30, 2017 |
|
December 31, 2016 |
| Balance Sheet Data: |
|
|
|
|
|
|
|
| Cash, cash equivalents and marketable
securities |
|
|
|
|
$ |
59,449 |
|
|
$ |
7,077 |
|
| Total assets |
|
|
|
|
|
67,555 |
|
|
|
53,514 |
|
| Total liabilities |
|
|
|
|
|
14,575 |
|
|
|
30,048 |
|
| Total equity |
|
|
|
|
|
52,980 |
|
|
|
4,066 |
|
| |
